Results 21 to 30 of about 6,313 (203)

Insulin/carbohydrates ratio during the first 6‐month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. An observational longitudinal study

Endocrinology, Diabetes & Metabolism, 2020
Background No data exist about the changes induced by the transition from first‐generation long‐acting insulins to second‐generation long‐acting analogues in the paediatric population.
Stefano Tumini, Olimpia Iacono, Laura Comegna, Elisabetta Fioretti, Paola Guidone, Gabriella Levantini, Daniele Panichi, Milena Catenaro, Ilaria Rossi, Flavia Amaro, Giusi Graziano, Maria Chiara Rossi, Paola Cipriano   +12 more
doaj   +1 more source

Effectiveness and safety of flexible therapeutic schemes including first- and secondgeneration basal insulins during a pediatric summer diabetes camp

Pediatric Reports, 2020
Outcomes of insulin analogues in pediatric diabetes camps are poorly investigated; no data is available about insulin degludec (IDeg).Our aim was to assess impact of insulin therapy adopted by the participants to a 4-day diabetes camp held in 2017 ...
Stefano Tumini, Laura Comegna, Elisabetta Fioretti, Paola Guidone, Gabriella Levantini, Daniele Panichi, Milena Catenaro, Ilaria Rossi, Flavia Amaro, Giusi Graziano, Maria Chiara Rossi, Paola Cipriano   +11 more
doaj   +1 more source

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials [PDF]

, 2013
Aim: To evaluate health-related quality of life (health utility) scores in patients with diabetes receiving insulin degludec (IDeg) or insulin glargine (IGlar).
Bjorner, JB, Christensen, T, Evans, M, Freemantle, N, Wolden, ML   +4 more
core   +1 more source

Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Degludec Due to Hypoglycaemic Variability

Frontiers in Endocrinology, 2018
Background: Cardiovascular disease is a frequent complication of type 1 diabetes (T1D). We evaluated the effectiveness of switching from glargine to degludec in reducing the cardiovascular risk factors, the Framingham risk score (FRS) and visceral ...
Valentina Guarnotta, Giulia Di Bella, Giuseppe Pillitteri, Alessandro Ciresi, Carla Giordano   +4 more
doaj   +1 more source

Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta-analysis of randomised controlled trials. [PDF]

Diabetes Obes Metab
Abstract Aims To evaluate the effectiveness and safety of early initiation of subcutaneous (SC) basal insulin in combination with intravenous insulin infusion (IVII), compared with IVII alone, for the management of diabetic ketoacidosis (DKA). Materials and Methods A systematic search of PubMed, Embase, Scopus, and the Cochrane Library was conducted to
Thammakosol K, Vongtangton P, Numthavaj P, Auttara-Atthakorn A, Sriphrapradang C.   +4 more
europepmc   +2 more sources

Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus [PDF]

, 2013
BACKGROUND: Management of diabetes in elderly subjects is complex and careful management of glucose levels is of particular importance in this population because of an increased risk of diabetes-related complications and hypoglycaemia. OBJECTIVE: The aim
F. Søndergaard, G. Koehler, G. Treiber, H. Haahr, H. Hastrup, J. K. Mader, K. Glettler, M. Urschitz, M. Wolf, S. Deller, S. Korsatko, T. R. Pieber   +11 more
core   +1 more source

Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial [PDF]

, 2016
We compared changes in blood glucose (BG) and risk of hypoglycaemia during and after exercise in 40 patients with type 1 diabetes (T1D) treated with insulin degludec (IDeg) or insulin glargine (IGlar) in a randomized, open-label, two-period, crossover ...
Richard Bracken, Steve Bain
core   +1 more source

In search of the ideal basal insulin: Does the new-generation ultra-long-acting insulin, degludec, provide the answer? [PDF]

, 2013
published_or_final_versio
Hui, YLE, Lam, KSL
core   +1 more source

Efficacy and safety of ultra-long-acting insulin degludec

Therapeutic Advances in Endocrinology and Metabolism, 2012
All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with insulin. Nonadherence to insulin regimen can impact glycaemic control.
Ammar Wakil, Stephen L. Atkin
doaj   +1 more source

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study [PDF]

, 2013
Aims/hypothesis: Insulin degludec (Des(B30)LysB29(γ-Glu Nε-hexadecandioyl) human insulin; IDeg) is a new basal insulin with an ultra-long flat action profile.
AE Gold, AJ Garber, B Raju, B Zinman, BM Frier, CG Fanelli, CR Bowie, D Wechsler, F Smeeton, I Jonassen, IJ Deary, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, KI Birkeland, O Tschritter, P Galassetti, P Rossetti, PA Goldberg, RE Ratner, RE Ratner, RJ McCrimmon, RM Reitan, RT Wilkinson, S Dagogo-Jack, S Heller, S Heller, SCL Gough, SN Davis, T Heise, UK Hypoglycaemia Study Group, V McAulay, World Medical Association   +30 more
core   +2 more sources